Germany’s Grand Coalition Offers Pharma Little Certainty, Except For Continued Discounts
This article was originally published in The Pink Sheet Daily
Germany’s new grand coalition government includes a health minister with no background in health care.
You may also be interested in...
After a disappointing assessment from Germany’s two reimbursement bodies, Janssen has opted to withdraw it diabetes drug, believing it cannot secure a competitive price.
A deal struck between Germany’s health insurance funds and Astra Zeneca/Bristol Myers Squibb means the drug manufacturers are ready to start supplying the drug again to the country’s health service.
This month’s European Notebook scans the horizon for European legislative and regulatory changes affecting the pharmaceutical industry in the next 12 months, including drug price freezes in Germany and the U.K., the heated debate over clinical trial data transparency, the start of the EU unitary patent, and more.